NCE-1 Intelligence & Market Opportunity

Korsuva

Difelikefalin

Antipruritic

Intravenous Solution

Approval Date

23-Aug-21

NCE-1 Date

23-Aug-25

NCE Date

23-Aug-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.1892

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

104

2030

107

2031

112

2032

118

Molecule profile

Details & specifications

Molecule

Difelikefalin

Innovator

VIFOR (INTERNATIONAL), INC.

Dosage Form

Intravenous Solution

Strength

EQ 0.065 mg base/1.3 mL (EQ 0.05 mg base/mL)

Therapeutic Category

Antipruritic

Usage

To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.